Pacific af study
WebMulticenter, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study Comparing the Safety of the Oral FXIa Inhibitor Asundexian With Apixaban in Patients With Atrial Fibrillation: PACIFIC AF. Minute CME/CE™. 0.00 of 0.00 program credits. Claim (0.00 credits) WebApr 6, 2024 · The current PACIFIC-AF study was conducted to determine the optimal dose of asundexian and to compare the incidence of bleeding between asundexian and apixaban …
Pacific af study
Did you know?
WebStudy design. PACIFIC-AF. was a multicentre, randomised, double-blind, double-dummy phase 2 trial comparing two doses of asundexian with standard dosing of apixaban. The …
WebPACIFIC-AF. Research type. Research Study. Full title. Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 … WebJan 25, 2024 · The PACIFIC-AF trial was the first study to investigate FXIa inhibition for stroke prevention in patients with AF. The bleeding-rate results are in accordance with previous Phase 2 studies of asundexian in VTE prevention. 4 Furthermore, the PACIFIC-AF trial included patients representative of most studies investigating anticoagulation ...
WebApr 9, 2024 · In this randomised, double-blind, phase 2 dose-finding study, we compared asundexian 20 mg or 50 mg once daily with apixaban 5 mg twice daily in patients aged 45 years or older with atrial fibrillation, a CHA DS -VASc score of at least 2 if male or at least 3 if female, and increased bleeding risk. WebPACIFIC-AF (Completed) Randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to a NOAC (apixaban) in patients with atrial fibrillation (AF) Medicine
WebApr 25, 2024 · In the PACIFIC-AF clinical trial, Jonathan P. Piccini, and colleagues identified an optimal dose for, asundexian, a novel inhibitor of coagulation factor XIa (FXIa), and further compared its incidence of bleeding to that of apixaban in patients with AF.
WebMar 11, 2024 · Save this study Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack … dpo\u0026g ltdWebPACIFIC-AF. Research type. Research Study. Full title. Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaban in patients with atrial fibrillation. IRAS ID. 272690. Contact name. Gregory Lip. Contact email. dpot shopping d\\u0026dWebApr 3, 2024 · In the PACIFIC-AF trial -- a phase 2 study funded by Bayer AG, which manufactures the investigative therapy -- the researchers focused on bleeding outcomes … dpo tramvaj hračkaWebAug 28, 2024 · In the phase II PACIFIC-AMI study, the investigators assessed the novel factor XIa inhibitor asundexian, which is being developed by Bayer and was shown previously in the phase II PACIFIC-AF trial of patients with atrial fibrillation to lessen bleeding relative to apixaban (Eliquis; Bristol Myers Squibb). dp O\\u0027HaraWebApr 3, 2024 · PACIFIC-AF is a phase two study. And it's looking at understanding the dosing of asundexian, a small molecule that inhibits factor XI and is minimally lurinally cleared. We used 20 milligrammes and 50 milligrammes once daily of asundexian and … radio bob punkWebApr 6, 2024 · In the PACIFIC-AF clinical study, the bleeding rate for the key endpoint (ISTH major or clinically relevant non-major bleeding) was 67% (incidence proportion) to 0.33). The once-daily therapy that selectively modulates blood clotting The FXIa inhibitor Asundexian is being investigated as a new treatment option for the prevention of thrombosis. radio boemi uzivoWebApr 3, 2024 · Treatment with the Factor XI activity inhibitor asundexian results in significantly lower rates of bleeding compared with apixaban and is well-tolerated, according to new data from the Phase 2 dose-finding PACIFIC-AF trial. Data from the trial were reported Sunday at the American College of Cardiology’s 71st Annual Scientific Session in ... dp ostrava